Business Wire

BIOCORP

17.2.2021 08:02:10 CET | Business Wire | Press release

Share
BIOCORP Signs Two New Partnerships With Mallya Technology

Regulatory News:

BIOCORP (FR0012788065 - ALCOR / Eligible PEA PME) (Paris:ALCOR), a French company specialized in the design, development and manufacturing of innovative medical devices, today announces the signature of new partnerships with Health2Sync and SocialDiabetes, companies headquartered in Taiwan and Spain, respectively.

These two partnerships involve the integration of Mallya, the connected device dedicated to insulin pens, with the digital applications developed by Health2Sync and SocialDiabetes to improve the quality of care for patients with diabetes.

In detail, the platform developed by SocialDiabetes (CE marked and FDA 510K) allows self-monitoring of insulin doses and offers personalized recommendations to patients. All of the data collected feeds a telemedicine platform using augmented intelligence for physicians and specialized call centers. To date, this platform is used by 250,000 patients with diabetes, mainly in Spain, Mexico, Colombia and Chile.

Health2Sync’s app, through its analytics engine, provides personalized recommendations and nudges concerning meals, exercise, and blood glucose management, delivered in a compelling way that encourages users to stay adherent to treatment plans. Health2Sync’s Patient Management Platform utilizes decision support modules for healthcare providers to deliver effective interventions that are also scalable, with insulin dosing as an example. The patient management platform is deployed in over 260 of diabetes care institutions in Taiwan, Malaysia and Japan, and the mobile app is used by more than 600,000 patients in Taiwan, Japan, USA, Hong Kong, Malaysia, Singapore and Australia.

Patients using these digital solutions will be able to automatically synchronize the data recorded by their Mallya sensor, thus benefiting from a complete monitoring offer combining glycemic data analysis and insulin dose feedback. This information can be transmitted in real time to treating physicians via a devoted portal to improve the quality of dialogue with patients, optimize treatment plans and offer personalized recommendations.

Éric Dessertenne, CEO of BIOCORP, explained: “These new partnerships come at a time when our teams are preparing for the large-scale commercial launch of Mallya, which is already compatible with almost all disposable pens on the market. Its integration with the most widely used applications in local markets is a great advantage for the rapid adoption of Mallya in these countries. Health2Sync and SocialDiabetes will enable us to accelerate our penetration in Asia and some Latin American countries, geographical areas where the diabetic population and the use of connected medicine are highly developed".

”Health2Sync bridges the lengthy gap between doctor visits by enabling frequent digital touch points between patients and healthcare providers. Insulin dosing data captured by Mallya will significantly enhance the experience of patients on insulin “said Ed Deng, Co-Founder and CEO of Health2Sync. “We expect better adherence and improved outcomes that come as a result of making data available to patients and healthcare providers .”

“We are thrilled to initiate this agreement with Biocorp. Mallya sensor is a world-class player and represents the type of high-quality technology we want to bring to our customers. Patients increasingly demand combined solutions that provide them with high connectivity and data driven personalized support. This alliance with Biocorp is a big step toward the digital health ecosystem the market is waiting for . “said María Jesús Salido, cofounder & CEO of Social Diabetes.

ABOUT HEALTH2SYNC
Founded in 2013, Health2Sync provides a comprehensive health-management platform for people with chronic conditions. Its products combine mobile, cloud, and data analytics, enabling patients to obtain personalized care and allows care providers and family to care for patients remotely. With the largest network of clinics and hospitals, it is the leading solution in Asia that brings an effective, yet scalable solution to diabetes management.
For more information, please visit https://www.health2sync.com

ABOUT SOCIAL DIABETES
SocialDiabetes is set to become one of the best solutions to foster the digital management of diabetes. Leader in Spanish speaking markets, the company, headquartered in Barcelona with offices in the UK, and Ciudad de Mexico was first created to meet the needs of Victor Bautista, a Type 1 diabetes patient and current CTO & co-founder. A company of patients working for patients, SocialDiabetes provides a system that synchronizes with multiple devices, easily connect patients with the healthcare professionals that are treating them and provides relevant information for decision making in one place.
For more information, please visit www.socialdiabetes.com

ABOUT BIOCORP

Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press release

White s.r.o., exclusive owner of the VELOCIFERO brand, takes action in China to protect its intellectual property rights. Initial measures in Chongqing and Taizhou have already resulted in the seizure of vehicles alleged to be counterfeit. VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware

LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press release

CapitalG leads Series C funding round at a $3B valuation to advance LangChain's agent engineering platform LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and

Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release

Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr

SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release

Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,

SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release

Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye